Quarterly Statement Of Cash Flows

OncoTherapy Science, Inc. - Filing #7329199

Concept 2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
As at
2022-03-31
Quarterly statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,285,713,000 JPY
-1,006,572,000 JPY
-1,116,193,000 JPY
-1,116,420,000 JPY
Impairment losses
154,564,000 JPY
21,553,000 JPY
Interest expenses
218,000 JPY
JPY
Decrease (increase) in trade receivables
87,484,000 JPY
276,641,000 JPY
Decrease (increase) in inventories
25,618,000 JPY
131,423,000 JPY
Other, net
-16,233,000 JPY
-29,993,000 JPY
Subtotal
-1,225,319,000 JPY
-775,843,000 JPY
Interest paid
-109,000 JPY
JPY
Income taxes paid
-2,561,000 JPY
-2,896,000 JPY
Net cash provided by (used in) operating activities
-1,227,990,000 JPY
-794,901,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-2,627,000 JPY
-5,393,000 JPY
Proceeds from sale of property, plant and equipment
JPY
476,000 JPY
Net cash provided by (used in) investing activities
-33,354,000 JPY
-20,319,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
682,552,000 JPY
JPY
Other, net
-2,000 JPY
JPY
Net cash provided by (used in) financing activities
671,365,000 JPY
95,950,000 JPY
Net increase (decrease) in cash and cash equivalents
-589,978,000 JPY
-719,271,000 JPY
Cash and cash equivalents
527,656,000 JPY
1,117,635,000 JPY
1,836,906,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.